ORGO Organogenesis Holdings (A)

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences:

The Cantor Fitzgerald Global Healthcare Conference at the New York Marriott Marquis in New York, NY

  • Management will participate in a fireside chat on Wednesday, September 3 at 2:10 p.m. Eastern Time.

The Morgan Stanley Global Healthcare Conference at the Sheraton Times Square in New York, NY

  • Management will participate in a fireside chat on Wednesday, September 10 at 2:35 p.m. Eastern Time

Webcasts of the fireside chat sessions will be accessible by visiting the “News & Events” section on the “Investor Relations” page of Organogenesis’s website Archives of the webcasts will be available for replay following the conference for approximately 30 days.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit



Investor Inquiries:
ICR Healthcare
Mike Piccinino, CFA
 

Press and Media Inquiries:
Organogenesis
 
EN
27/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Organogenesis Holdings (A)

 PRESS RELEASE

Organogenesis Holdings Inc. to Participate in Upcoming Investor Confer...

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences: The Cantor Fitzgerald Global Healthcare Conference at the New York Marriott Marquis in New York, NY Management will partic...

 PRESS RELEASE

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Resu...

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared...

 PRESS RELEASE

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 20...

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025 CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Easter...

 PRESS RELEASE

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment ...

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the Centers for Medicare & Medicaid Services’ (CMS) proposed new payment approach for skin substitutes/cellular and tissue-based ...

 PRESS RELEASE

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Resul...

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to n...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch